Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics appoints new additions to board of directors

Stefano Buono and Richard Van Duyne join the biopharma

AbeonaAbeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the appointment of Stefano Buono and Richard Van Duyne.

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.

He said: “Abeona’s ambitious gene and cell therapies have the promise to bring treatments to patients for whom there are currently no treatment options available.

“Its mission to bring relief and an extended, better quality of life to patients, many of whom are children, is closely aligned with my own values, and I am happy to be able to contribute to the company.”

Van Duyne, on the other hand, has previously held executive-level business development positions, which led him to serve as global head of business development for Daiichi Sankyo.

He said: “I am excited to be joining Abeona’s board at such a time of momentum for the company and the gene therapy space as a whole.

“I believe Abeona’s pipeline has significant potential to bring transformative therapies to patients with devastating, life-threatening diseases.”

31st May 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics